News
Adding elotuzumab to lenalidomide/dexamethasone can prolong survival in relapsed/refractory myeloma
BOSTON – The overall survival advantage with elotuzumab was observed in all prespecified patient subgroups, including older patients, those with...
News
CT103A elicits responses after prior CAR T-cell relapse
BOSTON – Three of four patients who had failed a prior CAR T-cell therapy achieved a stringent complete response after CT103A.
News
Melflufen-dexamethasone active in patients with relapsed/refractory myeloma and EMD
BOSTON – Melflufen plus dexamethasone produced similar response rates in patients with and without extramedullary disease.
Video
Could home care replace inpatient HSCT?
Researchers are conducting phase 2 trials comparing patients who receive all posttransplant care at home with patients treated in the hospital or...
News
Fox Chase faculty receive grants for cancer research, education
One researcher will examine burnout among physician assistants working in oncology.
News
U.S. and African programs aim to improve understanding, treatment of sickle cell disease
The various programs include efforts to build a registry for patients with sickle cell disease and ways to optimize the use of hydroxyurea in...
News
CK doesn’t seem to affect OS in CLL patients taking idelalisib
Data from two clinical trials of idelalisib showed no significant difference in overall survival between patients with and without complex...
News
Nivolumab falls short in ccRCC patients with brain metastases
Nivolumab produced an intracranial response rate of 12% in patients with clear cell renal cell carcinoma and previously untreated brain metastases...
News
Two iron chelators better than one for thalassemia major
In a single-center study, deferasirox plus deferoxamine significantly decreased cardiac iron and serum ferritin, but deferasirox alone did not.
Article
Researchers win grants to study real-world cancer data
Investigators received a National Institutes of Health R21 grant and CancerLinQ Discovery Research Support Grants.
News
Severe lipodystrophy linked to pembrolizumab
A 47-year-old woman developed severe lipodystrophy after receiving pembrolizumab to treat metastatic melanoma.
News
Combo produces responses in triple-class refractory myeloma
Selinexor plus low-dose dexamethasone produced a response rate of 26% in patients who were refractory to at least one proteasome inhibitor, one...
News
New transfusion guidelines for thalassemia
Experts discussed recommendations for alpha and beta thalassemia as well as non–transfusion dependent thalassemia.
News
FDA approves fedratinib for myelofibrosis
Fedratinib is approved to treat adults with intermediate-2 or high-risk primary or secondary myelofibrosis.
News
Review reveals lack of data on mild hemophilia A
A review of 17 studies showed limited and inconsistent data on bleeding, joint pain, quality of life, and other outcomes.